MedPath

Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump

Not Applicable
Terminated
Conditions
Type I Diabetes
Registration Number
NCT03653533
Lead Sponsor
ARAIR Assistance
Brief Summary

This study compares the apparition of hypoglycaemia in type I diabetic patients between 2 phases: the one without the use of SmartGuard® function and the one with the use of SmartGuard® function.

Detailed Description

The aim of this study is to compare SmartGuard® function with captor and insulin pump to improve the glycemia stability in real condition.

There are several phases:

* phase 1: insulin pump without captor (12 weeks)

* phase 2: insulin pump with captor and without SmartGuard® function (4X6 days; 4 weeks)

* phase 3: insulin pump with captor and with SmartGuard® function (6X6 days; 6 weeks)

* phase 4: insulin pump without captor (4 weeks)

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
8
Inclusion Criteria
  • type I diabetic patients undr basal/prandial diet
  • treated by insuline
  • with no insuline pump during at least 3 months
  • with HbA1C dosed during the 3 months before inclusion
Exclusion Criteria
  • minor patients
  • pregnant woman
  • already participating to another studies

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Primary Outcome Measures
NameTimeMethod
Occurrence of hypoglycemia between a phase with no SmartGuard® function and a phase with SmartGuard® function6 days

The primary outcome is the area between the glycemic curve and the hypoglycemic level (70 mg/dL), measured between the 6 last days of the phase without SmartGuard® function and the 6 last days with the use of SmartGuard® function

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Pole Sante Sud Le Mans

🇫🇷

Le Mans, France

Pole Sante Sud Le Mans
🇫🇷Le Mans, France
© Copyright 2025. All Rights Reserved by MedPath